Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, United States; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, United States.
Department of Dermatology, Boston University School of Medicine, Boston, MA, United States; Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, United States.
Methods Enzymol. 2023;682:289-318. doi: 10.1016/bs.mie.2022.09.007. Epub 2022 Dec 24.
Phosphatase and tensin homolog is a lipid phosphatase that serves as the major negative regulator of the PI3K/AKT pathway. It catalyzes the 3'-specific dephosphorylation of phosphatidylinositol (3,4,5)-trisphosphate (PIP) to generate PIP. PTEN's lipid phosphatase function depends on several domains, including an N-terminal segment spanning the first 24 amino acids, which results in a catalytically impaired enzyme when mutated. Furthermore, PTEN is regulated by a cluster of phosphorylation sites located on its C-terminal tail at Ser380, Thr382, Thr383, and Ser385, which drives its conformation from an open to a closed autoinhibited but stable state. Herein, we discuss the protein chemical strategies we used to reveal the structure and mechanism of how PTEN's terminal regions govern its function.
磷酸酶和张力蛋白同源物是一种脂质磷酸酶,作为 PI3K/AKT 途径的主要负调节剂。它催化磷脂酰肌醇(3,4,5)-三磷酸(PIP)的 3'-特异性去磷酸化,生成 PIP。PTEN 的脂质磷酸酶功能依赖于几个结构域,包括跨越前 24 个氨基酸的 N 端片段,当突变时会导致酶的催化活性受损。此外,PTEN 受到其 C 末端尾部上的一系列磷酸化位点的调节,这些位点位于 Ser380、Thr382、Thr383 和 Ser385 上,这些位点驱动其构象从开放的自动抑制但稳定状态转变为关闭的自动抑制但稳定状态。在此,我们讨论了我们用于揭示 PTEN 末端区域如何控制其功能的结构和机制的蛋白质化学策略。